Literature DB >> 19593185

Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.

Hiroyoshi Takeuchi, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Haruo Kashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19593185     DOI： 10.1097/JCP.0b013e3181accfec

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  8 in total

1.  Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide.

Authors:  François Montastruc; Rui Nie; Simone Loo; Soham Rej; Sophie Dell'Aniello; Joëlle Micallef; Samy Suissa; Christel Renoux
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 21.596

2.  Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.

Authors:  Chi-Un Pae; Alberto Chiesa; Laura Mandelli; Ashwin A Patkar; Sara Gibiino; Alessandro Serretti
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.

Authors:  Hiroyoshi Takeuchi; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-06-05       Impact factor: 4.530

4.  Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.

Authors:  Masayuki Takase; Nobuhisa Kanahara; Yasunori Oda; Hiroshi Kimura; Hiroyuki Watanabe; Masaomi Iyo
Journal:  J Psychopharmacol       Date:  2015-03-03       Impact factor: 4.153

5.  Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.

Authors:  G Raghuthaman; R Venkateswaran; R Krishnadas
Journal:  BJPsych Open       Date:  2015-12-14

Review 6.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

7.  Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.

Authors:  Jun Ishigooka; Kazuyuki Nakagome; Tetsuro Ohmori; Nakao Iwata; Ken Inada; Jun-Ichi Iga; Taro Kishi; Kiyoshi Fujita; Yuka Kikuchi; Toshiaki Shichijo; Hideaki Tabuse; Shotatsu Koretsune; Hiroshi Terada; Haruko Terada; Toshifumi Kishimoto; Yuichiro Tsutsumi; Yoshiki Kanda; Kazutaka Ohi; Kanji Sekiyama
Journal:  Psychiatry Clin Neurosci       Date:  2021-11-17       Impact factor: 12.145

8.  Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.

Authors:  Chia-Hao Ma; Hung-Yu Chan; Ming H Hsieh; Chen-Chung Liu; Chih-Min Liu; Hai-Gwo Hwu; Ching-Hua Kuo; Wei J Chen; Tzung-Jeng Hwang
Journal:  Ther Adv Psychopharmacol       Date:  2022-01-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.